CirculatingBRAFV600Ein the Diagnosis and Follow-Up of Differentiated Papillary Thyroid Carcinoma
Open Access
- 1 August 2013
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 98 (8) , 3359-3365
Abstract
Context: Cell-free nucleic acids circulating in plasma are considered a promising noninvasive tool for cancer monitoring. BRAFV600E mutation in cell-free DNA (cfDNA) could represent an appropriate marker for papillary thyroid carcinoma (PTC). Objective: Our aim is to investigate the role of BRAFV600E-mutated allele in cfDNA as a marker for the diagnosis and follow-up of PTC. Study Design: BRAFV600E allele was detected and quantified by an allele-specific real-time quantitative PCR assay in plasma from 103 patients affected by nodular goiter. As control populations, we enrolled 49 healthy subjects and 16 patients with non-nodular thyroid diseases. Results: The percentage of circulating BRAFV600E was significantly different between patients and controls and throughout different cytological categories of ultrasound-assisted fine-needle aspiration. Patients with a histopathological diagnosis of PTC showed a higher percentage of circulating BRAFV600E (P = .035) compared to those with benign histology. In 19 patients, a second blood draw, taken 3–6 months after surgery, showed a lower percentage of BRAFV600E in cfDNA than the presurgical sample (P < .001). The diagnostic performance of circulating BRAFV600E was assessed by receiver operating characteristic curve analysis resulting in an area under the curve of 0.797. A cutoff value was chosen corresponding to maximum specificity (65%) and sensitivity (80%). On this basis, we evaluated the predictive value of BRAFV600E in Thy 3 patients with a resulting positive predictive value of 33% and a negative predictive value of 80%. Conclusions: The results of the present study provide encouraging data supporting the possibility to take advantage of circulating BRAFV600E in the management of PTC.Keywords
This publication has 30 references indexed in Scilit:
- Study of peripheral BRAFV600Emutation as a possible novel marker for papillary thyroid carcinomasHead & Neck, 2012
- Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate CytologyNew England Journal of Medicine, 2012
- Molecular genetics and diagnosis of thyroid cancerNature Reviews Endocrinology, 2011
- Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variantHuman Pathology, 2011
- The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204)Biochemical and Biophysical Research Communications, 2011
- Cell-free DNA in the blood as a solid tumor biomarker—A critical appraisal of the literatureClinica Chimica Acta, 2010
- Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patientsClinica Chimica Acta, 2010
- Thyroid Cancer Epidemiology and Prognostic VariablesClinical Oncology, 2010
- American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: Executive Summary of recommendationsJournal of Endocrinological Investigation, 2010
- Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomasHead & Neck, 2009